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Abstract
Objective. This study aimed to measure the duration and recovery rate of olfactory loss in
patients complaining of recent smell loss as their prominent symptom during the coronavirus
disease 2019 outbreak.
Method. This was a prospective telephone follow-up observational study of 243 participants
who completed an online survey that started on 12 March 2020.
Results. After a mean of 5.5 months from the loss of smell onset, 98.3 per cent of participants
reported improvement with a 71.2 per cent complete recovery rate after a median of 21 days.
The chance of complete recovery significantly decreased after 131 days from the onset of loss
of smell (100 per cent sensitive and 97.7 per cent specific). Younger age and isolated smell loss
were associated with a rapid recovery, whereas accompanying rhinological and gastrointestinal
symptoms were associated with longer loss of smell duration.
Conclusion. Smell loss, occurring as a prominent symptom during the coronavirus disease
2019 pandemic, showed a favourable outcome. However, after 5.5 months from the onset,
around 10 per cent of participants still complained of moderate or severe hyposmia.
Introduction
Coronavirus disease 2019 (Covid-19) is an ongoing viral pandemic that started in China
in December 2019 and rapidly spread to the other countries of the world.1 The World
Health Organization (WHO) highlighted the triad of fever, cough and shortness of breath
in the definition of a suspected and probable case of Covid-19 in the early guidelines.2 At
the same time as the Covid-19 pandemic, there was a rapid increase in self-reported olfac-
tory dysfunction.3 In February 2020, smell and taste dysfunction were identified as a
symptom of Covid-19 in a survey of neurological manifestations of the disease.4
Further studies confirmed the association between Covid-19 and chemosensory dysfunc-
tion with a wide range of reported prevalence from 3.2 per cent up to 98 per cent for loss
of smell.5
By 9 May 2020, studies had provided sufficient evidence for the WHO to add loss of
smell alongside other less common symptoms of Covid-19, and on 7 August, patients
with sudden anosmia or ageusia without a known underlying cause were defined as a
probable case of Covid-19.6,7 Different factors were suggested to affect the prevalence
of smell loss in various studies, including demographic factors (age, gender), the severity
of the disease, and the methodology and design of the study. It seemed that smell loss was
more prevalent among younger people, out-patient cases, females, Caucasians and
whether the olfaction had been assessed objectively.5,8–10 Smell loss was even shown to
be related to the prognosis of Covid-19. Lower hospital and intensive care unit admission
rates, lower rates of acute respiratory distress syndrome or a need for intubation are asso-
ciated with the presence of olfactory loss.11,12
Loss of smell after a respiratory infection is not unique to Covid-19, and viruses such
as adenovirus, rhinovirus, coronavirus and influenza are already known as aetiological
factors.13 Although olfactory dysfunction is often accompanied by other Covid-19 symp-
toms in many published reports, there is some evidence indicating that Covid-19 patients
can present with chemosensory dysfunctions as their sole symptom of the disease.14
Although the prognosis of post-viral olfactory loss is not exactly clear and reported recov-
ery rates vary in related studies, early reports, which are mostly from Europe, suggest a
more favourable prognosis for olfactory loss encountered in confirmed Covid-19 cases
compared with previously described post-viral olfactory loss.15,16 However, as was seen
with prevalence rates, reported olfactory recovery rates vary between studies, and several
factors have been reported to be associated with the prognosis of smell loss in Covid-19
cases.17–20
Healthy, young out-patients with subtle or no symptoms
are not prioritised for real-time polymerase chain reaction in
the diagnostic protocols in areas with limited resources.21
Because of the high incidence of olfactory dysfunction in
Covid-19 cases, this study aimed to investigate the duration
and recovery rate of olfactory loss encountered in cases with
mild or no additional Covid-19 symptoms (with no
Covid-19 confirmed tests) that occurred during the pandemic
in order to indicate the factors that may influence the duration
or recovery rate of olfactory dysfunction in these patients.
Materials and methods
Study population
An online survey by Bagheri et al.22 was run from 12 March to
8 April 2020. Out of 19 473 participants with smell loss, 6654
responders registered their phone numbers so their symptoms
could be followed. Participants were selected for inclusion in
this study if they had reported the absence of other accom-
panying Covid-19 symptoms (including cough, fever, short-
ness of breath, sore throat, myalgia, nausea or vomiting, and
diarrhoea) or rhinological symptoms (including runny nose,
sneeze, nasal congestion, nasal thick discharge and a need to
blow the nose).
Participants aged under 18 years, or those who had men-
tioned a history of previous olfactory problems, chemotherapy,
chronic respiratory infections, nasal polyps, head trauma, neu-
rodegenerative diseases, receipt of specified treatment for their
recent smell loss (including glucocorticoids, hydroxychloro-
quine or any antiviral medications) or those who could not
be reached by three calls on three separate days through the
provided telephone numbers were excluded.
Measurements and study design
In this prospective observational study, all eligible participants
were interviewed on the telephone about the severity of recent
smell loss at the onset and at the time of the interview (self-
assessed by an ordinal scale from one to five corresponding
to normal sense of smell, mild loss of smell, moderate loss
of smell, severe loss of smell or anosmia) and the duration
of the smell loss (the days since loss of smell onset to being
fully recovered).23
Additional Covid-19 symptoms, presenting in one week
prior until one week after the onset of loss of smell were self-
graded as: no symptoms, mild symptoms, moderate symptoms
and severe symptoms.24 Rhinological symptoms in the same
time limits were self-assessed based on the rhinological
subscale of Sino-Nasal Outcome Test-22 (a Likert scale of
1 to 5).25,26 Any diagnosis of Covid-19 by real-time polymerase
chain reaction or chest imaging in the participants or their fam-
ily members living in the same house or any recent smell loss in
the family members was also recorded. The participants were
followed up via telephone twice at least three months apart if
they did not report a return of olfaction to the baseline. The
patients who did not want to be followed up (despite their
first consent), had not answered the questions completely
(because of not remembering), had received medication during
the follow ups, who reported moderate or severe rhinological
or Covid-19 symptoms, or who were hospitalised were excluded
from the analysis. Complete recovery was defined as self-
reported restoration of smell ability, whereas partial recovery
was defined as improvement in olfactory ability.
Statistical analysis
The data were described as mean and standard deviation or
frequency (per cent). Chi-square or Fisher’s exact test was uti-
lised for assessing the relationship between categorical data
with time to recovery categories (in correspondence with
first and third quartile of time to complete recovery).
Subsequently, rapid and moderately recovered patients were
merged and odds ratios for measuring the effect size were cal-
culated. The significant variables were included in multiple
logistic models to assess the multiple relationships. The
receiver operating characteristic curve was used to classify
patients as with and without complete recovery, considering
the time passed from the onset of smell loss. Kaplan–Meier
estimates were reported to show the rate of complete recovery
from the onset of the smell loss. All analysis was performed
using SPSS® (version 24) statistical software. A p-value less
than 0.05 was considered significant.
Results
Study population demographic data and symptoms
Data of 243 participants were included in the final analysis
after application of inclusion and exclusion criteria. The
mean age of participants was 32.96 ± 9.47 years. The partici-
pants were from 16 different provinces of Iran, mainly from
Gilan (n = 120, 49.4 per cent), Tehran (n = 63, 25.9 per
cent), Alborz (n = 12, 4.9 per cent), Esfahan (n = 11, 4.5 per
cent) and Mazandaran (n = 11, 4.5 per cent). These provinces
were among the first provinces of the country to be affected by
Covid-19.27 One-hundred and fifty-five (63.8 per cent) partici-
pants were female, and 54 (22.2 per cent) reported they were
smokers. At the first follow up, 139 (57.2 per cent) participants
had not recovered completely. Of this group, 130 (93.5 per
cent) participants were reached in the second follow up.
Of 243 participants, 215 (88.5 per cent) reported total anos-
mia at the onset of the olfactory impairment. None of the
responders reported any Covid-19 or sinonasal signs and
symptoms in the original online survey. However, at the inter-
view, 175 responders (72 per cent) reported mild symptoms:
153 responders (59.1 per cent) reported at least one of the
Covid-19 symptoms and 66 responders (27.2 per cent)
reported at least one of the rhinological symptoms. Loss of
smell (with or without taste dysfunction) was reported as the
first symptom by 119 participants (49 per cent) and as the
sole symptom by 68 participants (28 per cent). None of the
participants had undergone real-time polymerase chain reac-
tion testing or had been evaluated by a computed tomography
scan of the chest. Ten participants (4.1 per cent) reported
Covid-19 diagnosis, and 77 participants (31.8 per cent)
reported new onset loss of smell in at least one family member
living at the same house. Accompanying symptoms are pre-
sented in Table 1.
Follow-up duration and final recovery rates
The mean total follow-up duration was 111.39 ± 59.34 days
(median: 151, mode: 47, range: 26–203 days). The first inter-
view was completed after a mean of 47.95 ± 12.44 days after
the onset of smell loss (median: 46, mode: 40, range: 26–91
days).
At the first telephone interview, 104 patients (40.3 per cent)
self-reported complete recovery. From the remaining 139 par-
ticipants, 130 could be followed up with the second interview
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after a mean of 165.99 ± 9.34 days after the onset of their smell
loss (median: 166, mode: 169, range: 142–203).
At the end of the study, those who had not completely
recovered were followed for a mean of 149.38 ± 41.25 in ‘par-
tial recovery’ (median: 164, mode: 166, range: 38–203) and
163.75 ± 10.81 in ‘no recovery’ groups (median: 161, mode:
154, range: 154–179). Finally, 239 participants (98.3 per
cent) reported improvement: 173 (71.2 per cent) reported
complete recovery and 66 (27.1 per cent) reported partial
recovery. Mild, moderate and severe hyposmia was reported
by 45 (18.5 per cent), 21 (8.6 per cent) and 4 (1.6 per cent)
patients, respectively. No one reported anosmia at the last fol-
low up.
Factors influencing complete recovery
The mean age of patients with and without complete recovery
was 33.16 ± 10.24 and 32.48 ± 7.34 years, respectively
( p = 0.614). Complete recovery was reported significantly
more frequently in the patients with a family history of recent
smell impairments (80.5 per cent (n = 62) vs 67.1 per cent
(n = 110); p = 0.031) and less in those who reported fever as
an accompanying symptom (58.3 per cent (n = 28) vs 74.6
per cent (n = 144); p = 0.026). Furthermore, the odds of com-
plete recovery in patients without fever were 2.10 times higher
in comparison with patients with fever (95 per cent confidence
interval (CI): 1.08–4.07). There were no significant relation-
ships between other symptoms and complete recovery. The
rates of complete recovery were not significantly different
between participants with rhinological symptoms, Covid-19
symptoms or those with isolated smell loss.
Duration of smell loss and predictive factors
The smell loss was self-reported to last for a mean of 32.54 ±
31.48 days (median: 21, mode: 30, range: 3–210) until com-
plete recovery. Complete recovery of smell loss within the
mean follow up of 111 days in 234 responders who could be
reached at the last follow up showed the rate of improvement
to be 56.2, 70.1, 71.5 and 74.7 per cent at 50, 100, 150 and 200
days following onset of smell loss, respectively (Figure 1).
In order to evaluate the factors influencing the duration of
the smell loss, completely recovered participants were divided
into three groups based on the first and third quartile of the
time to recovery: rapid recovery (1–10 days), moderate recov-
ery (11–45 days) and delayed recovery (more than 45 days).
Rapidly recovered participants were significantly younger
compared with the delayed recovery participants (31.3 ± 8.69
vs 35.55 ± 9.43; p = 0.031). Patients with smell loss as the
sole symptom reported early recovery significantly more
frequently compared with those who had any Covid-19 or
sinonasal symptoms (88.7 per cent (n = 47) vs 73.1 per cent
(n = 87); p = 0.037).
Although the prevalence of nasal congestion, headache,
nausea or vomiting, and diarrhoea increased significantly in
those who had a longer recovery period (Table 2), there was
a statistically significant relationship only between diarrhoea
and delayed recovery in the multiple logistic models (odds
ratio = 4.65; p = 0.031; Table 3). However, the percentage of
the patients with at least one rhinological symptom who had
a delayed recovery was significantly higher (41.7 per cent
(n = 10) vs 18.9 per cent (n = 28); p = 0.020, odds ratio =
3.06, 95 per cent CI = 1.13–5.19).
The receiver operating characteristic curve was used to clas-
sify the patients according to gaining complete recovery, con-
sidering the time passed from the onset of the smell loss. It
showed that day 131 after the onset of olfactory dysfunction
was the best cut-off for predicting that participants would
not gain complete recovery (100 per cent sensitivity and
97.7 per cent specificity). The area under the receiver operating
characteristic was 0.98 (95 per cent CI: 0.97–100; Figure 2).
Discussion
This study was carried out on patients with sudden smell loss
that happened during the Covid-19 pandemic and who
reported mild Covid-19 or rhinological symptoms or no
accompanying symptoms at all. Although 98.3 per cent of par-
ticipants ultimately reported some improvement, the rate of
complete recovery reported after at least 4 months of follow
up was 71.2 per cent. Although no one reported anosmia,
1.6 per cent of respondents still complained of severe hypos-
mia, and 8.6 per cent reported moderate hyposmia at the
end of the study.
The reported chance of recovery in routinely encountered
post-viral olfactory loss ranged from 32 to 67 per cent, and
around 20 per cent of patients did not recover after 1 year of
viral infection.3,28 A review of articles published from 1
April to 31 October 2020 and focusing on the rate of recovery
in confirmed cases of Covid-19 was carried out (Table 4).29–67
In the confirmed Covid-19 patients, the reported rates of com-
plete recovery varied greatly (4 to 96 per cent for a 1-month
follow up and 63 to 91.4 per cent for a 2-month follow
up).29,52,57,64 The recovery rates for follow up of 3 and 6
months were reported to be 85.3 per cent and 86 per cent,
respectively.49,65 It should be emphasised that because
Covid-19 had not been confirmed by polymerase chain reac-
tion in our patients, they were considered to be probable
cases of Covid-19 according to WHO criteria. Their rate of
complete recovery of smell loss was more similar to the rate
of recovery of Covid-19 cases compared with other post-viral
olfactory impairment. Interestingly, even patients who
reported isolated smell loss self-reported a complete recovery
Table 1. The distribution of existing symptoms of participants
Signs and symptoms Total (n (%))
Coronavirus 19 symptoms 153 (59.1)
– Headache 63 (24.7)
– Myalgia 71 (27.4)
– Fever 55 (21.9)
– Cough 50 (19.3)
– Sore throat 44 (17)
– Dyspnoea 20 (7.7)
– Diarrhoea 20 (7.7)
– Nausea or vomiting 7 (2.7)
Rhinological symptoms 66 (27.2)
– Rhinorrhoea 47 (18.2)
– Sneeze 34 (13.2)
– Nasal congestion 16 (6.2)
– Nasal thick discharge 2 (0.8)
– Need to blow the nose 7 (2.9)
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rate of 77.9 per cent (in a mean follow-up time of 3.3 months
which lasted for a mean of 26 ± 25.12 days), which is well
above the reported rate of recovery for post-viral olfactory
impairment. These patients even showed a faster recovery per-
iod compared with the others.
Various factors have been reported to influence the rate of
recovery of smell loss in Covid-19 patients. The mean duration
of olfactory impairment was reported to be 8 to 9 days in a
pooled analysis of 20 studies.5 In our study, the duration of
smell loss was significantly shorter in those with lower age
and those who reported no additional symptoms besides the
smell loss. There is a controversy in the reported effect of
age on the duration of smell loss in Covid-19. Although
Levinson et al.68 reported a longer duration of smell loss in
patients aged over 40 years, patients with severe loss of smell
who recover later have been reported to be younger in 2
studies.17,18 In a study by Fjaeldstad,51 with a similar method-
ology and study population to this study (online survey for
out-patients with a mean age of 39.4 years who were mainly
without confirmation for Covid-19), there was no significant
effect of age on the time of recovery or recovery rates. As
transmembrane serine protease 2 expression is reported to
increase with older age, this may explain the negative effect
of older age on the recovery of the sense of smell in the
patients.69
The duration of smell loss was significantly longer in the
patients who reported nasal congestion or any rhinological
symptoms. Nasal congestion has been shown to be associated
with a slow resolution and lower recovery rate.20,44 In the pre-
sent study, nasal congestion did not affect the final complete
recovery rates, but it slowed down the process of smell recov-
ery. Only 10 per cent of the population with nasal congestion
completely recovered within the first 10 days, and a report of
rhinological symptoms increased the odds of the late recovery
(complete recovery after 45 days) by 3 times. This may be a
reflection of the conductive component effect (mucosal
oedema) on the suggested mechanism of smell impair-
ment.47,70,71 However, an increased level of inflammation,
induced by pre-existing rhinitis, may also be responsible.
Nasal goblet (secretory) cells and ciliated cells in the epithe-
lium of respiratory and gastrointestinal systems have shown
the highest angiotensin-converting enzyme 2 expression.72
Fig. 1. Kaplan–Meier estimates showing the rate of
regaining complete recovery (percentage) during the
follow-up time.
Table 2. The association between symptoms and time to recovery
Symptom
Time to complete recovery
P-value Odds ratio (95% CI)1–10 days (n (%))* 11–45 days (n (%))† >45 days (n (%))‡
Headache
– With 8 (18.2) 21 (47.7) 15 (34.1) 0.043 2.36 (1.09–5.10)
– Without 42 (32.8) 63 (49.2) 23 (18)
Diarrhoea
– With 1 (10) 3 (30) 6 (60) 0.011 5.95 (1.61–22.73)
– Without 49 (30.4) 80 (49.7) 32 (19.9)
Nausea or vomiting
– With 0 2 (33.3) 4 (66.7) 0.016 7.69 (1.5–43.48)
– Without 50 (30.3) 81 (49.1) 34 (20.6)
Nasal congestion
– With 1 (10) 4 (40) 5 (50) 0.04 3.88 (1.06–14.29)
– Without 49 (30.4) 79 (49.1) 33 (20.5)
Odds ratios show the odds of delayed complete recovery versus rapid or moderate complete recovery. *n = 50; †n = 84; ‡n = 38. CI = confidence interval
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The exact mechanism of diarrhoea is still unclear, and any cor-
relation between olfactory dysfunction and gastrointestinal
symptoms has not been reported previously.73 However, diar-
rhoea has been shown to be correlated with more severe sys-
temic inflammation in Covid-19 patients.74 It has also been
considered as a risk factor for a more severe and poor progno-
sis course of the disease in several studies.75–77 At the last fol-
low up, only 50 per cent (10 out of 20) of our participants with
diarrhoea reported complete recovery, and the patients with
diarrhoea had a 4.65 fold increased risk for delayed recovery.
The present study demonstrated that although improve-
ment of smell loss may happen with longer follow up, the
chance of complete recovery after 131 days from the onset of
smell loss dramatically decreases (100 per cent sensitive and
97.7 per cent specific). Total recovery was shown to be signifi-
cantly related to a short time from the onset of smell loss to the
onset of recovery.44 Vaira et al.32 also emphasised the role of
time passed since the clinical onset in improvement or total
recovery.
A lower complete recovery rate and a longer duration to
complete recovery was shown in this study compared with
some of the previous studies, perhaps because of the predom-
inantly female population, cases with severe loss of smell at the
beginning and the method of the patient selection. In the pre-
sent study, the majority of the participants were anosmic (88.5
per cent), and the remaining 11.5 per cent were reported to be
severely hyposmic. The severity of smell loss has been reported
to play a role in the prognosis. Longer recovery duration has
been reported for patients with severe loss of smell compared
with patients with milder impairment.17,18 Cases with severe
smell loss in a study by Izquierdo-Domínguez et al. were
younger, predominantly female and with a lower rate of pneu-
monia.17 Similarly, anosmia was found as a risk factor for later
recovery.19,20 On the contrary, in a study by Paolo there was no
significant difference in the time of resolution between hypos-
mic or anosmic patients.78
• Various recovery rates have been reported for sudden unexplained
anosmia encountered during the coronavirus disease 2019 (Covid-19)
pandemic
• Smell loss can be the prominent or sole symptom of Covid-19, although
other viruses can induce olfactory dysfunction
• After a mean of 5.5 months, the rate of improvement, complete recovery,
and moderate or severe hyposmia were 98.3, 71.2 and 10 per cent,
respectively
• Complete recovery was associated positively with recent smell loss in at
least one family member living with the patient and negatively with fever
• Younger age and isolated smell loss were associated with a rapid recovery,
and rhinological and gastrointestinal symptoms were associated with a
slow recovery
• After 131 days from the smell loss onset, the chance of regaining
complete recovery dramatically decreased
A study by Paderno et al. discussed that women self-report
recovery after a longer duration than men.20 Around 64 per
cent of the population in our study was female, which may
explain why less than 30 per cent of completely recovered
patients had a duration of fewer than 9 days. However, this
study did not show any significant differences in the rate of
recovery between the sexes.
Limitations
In this study, the included participants had subtle or no
Covid-19 symptoms and had not been tested by real-time
polymerase chain reaction test. Therefore, definite allocation
of the smell loss to Covid-19 or routine post-viral olfactory
impairment was impossible, which may be considered as a sig-
nificant limitation. The smell loss was self-assessed by an
ordinal scale that may have limited correlation with more
objective measures.79,80 In addition, we were unable to confirm
self-reported recovery rates with psychophysical testing
because of low compliance of paucisymptomatic participants
for in-person attendance in the hospital for the tests during
the pandemic.
Although the online surveys facilitate collecting informa-
tion with minimal burden on healthcare personnel, they are
prone to some biases. The results of this study show that subtle
symptoms may not be reported properly in an online survey.
This limitation was overcome by reconfirmation through
Table 3. The multiple logistic models for assessing the association between mentioned symptoms with later recovery
Symptom Odds ratio Standard error (beta) P-value
95% CI for odds ratio
Lower Upper
Diarrhoea 4.65 0.71 0.031 1.15 18.87
Nausea or vomiting 3.85 0.97 0.163 0.58 25.64
Nasal congestion 2.46 0.75 0.229 0.57 10.75
Headache 1.70 0.44 0.229 0.72 4.03
Fig. 2. The receiver operating characteristic curve to assess the efficacy of using the
time passed from the onset of smell loss to predict the probability of not regaining
complete recovery.
The Journal of Laryngology & Otology 5
Table 4. A review of the studies on olfactory dysfunction in Covid-19 which focused on smell loss recovery rate and duration
Authors Country
Followed cases
with OD (n) Covid-19 status Follow-up duration
Method of
assessment of
OD Recovery rate (%) Time to recovery
Lechien et al.29 Europe 357 Positive Mean ± SD of 9.2 ± 6.2 days Subjective 44 early recovery 96.6% in <15 days
Yan et al.12 USA 40 Positive <2 weeks Subjective 72.5 resolution 76.52% in <15 days





Positive Not reported Subjective 40 complete recovery & 16.7 partial
recovery
Mean ± SD of 7.4 ± 2.3 days for
complete recovery & 9.1 ± 3.6
days for partial recovery
Vaira et al.32 Italy 53 smell/taste
disorders
Positive Mean of 19.3 days Subjective &
objective
Subjective evaluation: 66 complete
recovery. Objective evaluation: 13.2
complete recovery
54.28% in <5 days
Lee et al.33 Korea 232 Positive Maximum of 40 days Subjective 94% recovery in the first 35 days Median of 7 days & most of
them within 3 weeks
Hopkins et al.34 UK 382 80% positive of
15 tested cases
>4 weeks Subjective 71 75% took more than 4 weeks
from the onset





Most took 10 days, then
reached a plateau
Lechien et al.36 Belgium 86 Positive with
RT-PCR or IgM,
IgG
Mean ± SD of 18 ± 11 days Subjective &
objective
Subjective evaluation: 0 complete
recovery. Objective evaluation: 38.3
normosmia.
Mean ± SD of 17 ± 11 days for
normosmics
Kosugi et al.37 Brazil 145 Positive Median of 31 days (range, 12–39) Subjective 52.6 complete recovery &
33.6 partial recovery
15 days
Dell’Era et al.38 Italy 237 Positive Median of 23 days Subjective 62.9 complete recovery Median of 10 days (range, 1–
25 days)
Chung et al.39 China 6 patients
subjectively
evaluated
Positive 14 days Subjective 50 Not reported
Chung et al.39 China 6 patients
objectively
evaluated
Positive 7–9 days Objective 66.6 Not reported
Paderno et al.40 Italy 283 Positive In-patients: mean ± SD of 15.9 ± 6.7
(range, 1–45) days; out-patients:
mean ± SD of 20.9 ± 7.4 (range, 6–45)
days
Subjective 52 complete recovery Mean ± SD of 9 ± 5 days
Freni et al.41 Italy 46 Positive Mean ± SD of 49.7 ± 18.9 days Subjective 82 resolution 5–8 days in 56% of patients
Sakalli et al.42 Turkey 88 Positive Mean ± SD of 4.3 ± 3.2 days
(range, 1–11)
Subjective 22.7 complete recovery &
55.7 partial recovery
Mean ± SD of 8.02 ± 6.41 days
Cervilla et al.43 Spain 44 Positive 1 month Objective 78 resolution 77% in >15 days












Gorzkowski et al.44 France 136 Positive Mean of 26 days Subjective 51.43 complete recovery Recovery started between
days 14 and 15 days in 78.4%
Boscolo-Rizzo
et al.45
Italy 113 Positive 4 weeks Subjective 48.7 complete recovery &
40.7 partial recovery
Mean of 11.2 days
Salmon Ceron
et al.46
France 48 Positive Mean ± SD of 15 ± 3 days Subjective 27.1 complete recovery &
72.9 partial recovery
Not reported
Jalessi et al.47 Iran 22 Positive Maximum 21 days Subjective 95.45 complete recovery Mean ± SD of 10.73 ± 8.26
days
D’Ascanio et al.48 Italy 7 in-patients and
19 out-patients
Positive By 30 days Subjective 85.7 resolution for in-patients &
84.3 resolution for out-patients
More than 5 days
Parente-Arias
et al.49
Spain 75 Positive Mean ± SD of 100.5 ± 3.3 days
(range, 91–108)
Subjective 100 improvement & 85.3 complete
recovery
Mean ± SD of 17.7 ± 8.9 days.
55.2% of them in the first
12 days
Barillari et al.50 Italy 207 Positive and
perhaps
untested.
Mean ± SD of 11.6 ± 7.4 days Subjective 61.9 recovery 1–15 days, 60% in <9 days
Fjaeldstad51 Denmark 100 42% positive
and 58%
untested
Mean of 33.5 days Subjective 44 complete recovery for smell loss Mean of 15.1 and 14.9 days
for positive and untested,
respectively
Le Bon et al.52 Belgium 72 Positive with
RT-PCR or IgM,
IgG
Mean of 37 days Subjective &
objective
4 complete recovery 63 normosmic A mean of 12 (range, 3–47)
days
Spadera et al.53 Italy 180 89.6% of tested
cases were
positive
Not reported Subjective 6.11 complete recovery 2–10 days
Moein et al.54 Iran 82 Positive Maximum of 8 weeks Objective 63 normosmia Not reported
Klopfenstein et al.55 France 37 Positive Maximum of 28 days Subjective 99.97 recovery Mean ± SD of 7.4 ± 5 days
Cocco et al.56 Italy 78 Positive Mean ± SD of 46.1 ± 19 days Subjective 51.3 smell recovery Within 20 days
Vaira et al57 Italy 117 smell/taste
disorders
Positive Maximum of 60 days Objective 91.4 recovery Mainly regressed within
30 days
Cho et al.58 China 39 Positive 4–6 weeks Subjective 71.8 complete recovery Mean ± SD of 10.3 ± 8.1 days
Rojas-Lechuga
et al.18
Spain 138 Positive Not reported Subjective 37.67 recovery Median of 4, 6 and 7 days for









France 751 Positive with
PCR or
serology
Mean ± SD of 47 ± 7 days Subjective 49 complete recovery & 14 partial
recovery
Mean ± SD of 10 ± 6 days for
complete recovery & 12 ± 8
days for partial recovery
Amer et al.19 Egypt 96 Positive 1 month Subjective 33.3 complete recovery &
41.7 partial recovery
Mean of 17 days for complete
recovery & mean of 11 days
for partial recovery
Hao Lv et al.16 China 39 Positive Not reported Subjective 89.7 complete recovery &
10.2 partial recovery










telephone interview; however, it was still prone to recall bias or
over-reporting because of prompting by the interviewer. On
the other hand, in this study, in 50 per cent of the cases, a
range of 14–28 days had passed from the initial loss of smell
to their participation. This data shows a significant number
of our participants were still suffering from smell loss after
at least two weeks, and that was the possible reason they
found the online survey in their searches and were more will-
ing to participate. In other words, some patients who had rap-
idly recovered may not have participated.
Conclusion
Because of the high number of patients with Covid-19, the
considerable prevalence of anosmia among the affected popu-
lation and the huge negative impact of anosmia on quality of
life, it is important to inform patients about favourable prog-
nosis. However, a dramatic decrease in the rate of complete
recovery happens after four months from the onset of smell
loss, which may necessitate considering any optional treat-
ments to start before this deadline. Although our patients
were not definite cases of Covid-19 by WHO criteria, patients
with smell loss as the sole symptom recovered significantly fas-
ter, whereas patients with rhinological or gastrointestinal
symptoms may have a longer recovery period.
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